In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Cagrilintide Weight Loss Results: What Patients in Louisiana Need to Know Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet